eligibility_summary
Eligible: ≥18, consent, advanced solid tumor with malignant pleural effusion needing drainage, prior standard therapy failed/none, B7‑H3–positive cells (tumor/effusion), ECOG 0–2, adequate CBC, liver, kidney, coag, prior AEs ≤G1, contraception, no intrathoracic drug in past month. Exclude: allergy, puncture contraindication, recent RT/surgery/steroids/other trials, prior B7‑H3 CAR‑T, infection/bleeding, major organ failure, autoimmune, allogeneic transplant, live vaccine <2 wks, HBV/HCV RNA+/HIV/syphilis, cognitive issues, pregnant/lactating, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: MT027, a CRISPR/Cas9-edited, allogeneic B7-H3–targeted CAR-T cell therapy (cellular immunotherapy) delivered intrapleurally in a Phase 1 dose-escalation study. Mechanism of action: Engineered T cells express a chimeric antigen receptor that binds B7-H3 (CD276) on tumor cells, triggering antigen-dependent T-cell activation, cytokine release, and cytotoxic killing, gene editing supports use as an allogeneic product. Targets: Tumor cells in the pleural cavity with B7-H3 overexpression (per IHC), including pleural mesothelioma and pleural metastases, engages T-cell activation/cytolytic pathways and the pleural tumor microenvironment. Objective: assess safety, tolerability, PK/PD, and determine RP2D.